The Lipid-Lowering Effect of Tenofovir/Emtricitabine: A Randomized, Crossover, Double-Blind, Placebo-Controlled Trial

Should the dose of tenofovir be reduced to 200-250 mg/day, when combined with protease inhibitors?

(2014) Andrew Hill et al.   Journal of the International AIDS Society

Lipid profile changes by high activity anti-retroviral therapy

(2013) M. Duro et al.   CLINICAL BIOCHEMISTRY

Association of tenofovir exposure with kidney disease risk in HIV infection

(2012) Rebecca Scherzer et al.   AIDS

Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents

(2012) Roger Bedimo et al.   AIDS

Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles

(2012) Georg Behrens et al.   ANTIVIRAL THERAPY

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile

(2012) José R. Santos et al.   PLoS One

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202

(2011) Grace A. McComsey et al.   JOURNAL OF INFECTIOUS DISEASES

A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206

(2010) Marisa Tungsiripat et al.   AIDS

Rapid Improvement in Fasting Lipids and Hepatic Toxicity After Switching From Didanosine/Lamivudine to Tenofovir/Emtricitabine in Patients With Toxicity Attributable to Didanosine

(2010) R. Palacios et al.   HIV CLINICAL TRIALS

Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients

(2010) M. A. Valantin et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

(2009) Roberto Ortiz et al.   AIDS

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

(2009) Jose R Arribas et al.   AIDS

Improvements in Subcutaneous Fat, Lipid Profile, and Parameters of Mitochondrial Toxicity in Patients with Peripheral Lipoatrophy When Stavudine is Switched to Tenofovir (LIPOTEST Study)

(2009) Esteban Ribera et al.   HIV CLINICAL TRIALS

Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients

(2009) Jose R Arribas et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A Randomized Comparative Trial of Continued Zidovudine/Lamivudine or Replacement With Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz-Treated HIV-1-Infected Individuals

(2009) Martin Fisher et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy

(2008) J. Ananworanich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY